<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="letter" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Med Surg (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Ann Med Surg (Lond)</journal-id><journal-id journal-id-type="pmc-domain-id">2638</journal-id><journal-id journal-id-type="pmc-domain">amsu</journal-id><journal-id journal-id-type="publisher-id">MS9</journal-id><journal-title-group><journal-title>Annals of Medicine and Surgery</journal-title></journal-title-group><issn pub-type="epub">2049-0801</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12768212</article-id><article-id pub-id-type="pmcid-ver">PMC12768212.1</article-id><article-id pub-id-type="pmcaid">12768212</article-id><article-id pub-id-type="pmcaiid">12768212</article-id><article-id pub-id-type="pmid">41496967</article-id><article-id pub-id-type="doi">10.1097/MS9.0000000000004340</article-id><article-id pub-id-type="publisher-id">AMSU-D-25-03061</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Artificial intelligence in cancer genomics: refining diagnosis of hereditary breast and ovarian cancer syndromes</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-5229-5052</contrib-id><name name-style="western"><surname>Khizar</surname><given-names initials="M">Muhammad</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><email>Muhammad.khizar@gau.edu.ge</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zaib</surname><given-names initials="M">Muhammad</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><email>Muhammad.zaib@gau.edu.ge</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-4741-7631</contrib-id><name name-style="western"><surname>Babar</surname><given-names initials="M">Meerab</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><email>meerab.babar05@gmail.com</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7618-3849</contrib-id><name name-style="western"><surname>Karimi</surname><given-names initials="H">Hasiba</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><email>hasibakrimi90@gmail.com</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1817-7800</contrib-id><name name-style="western"><surname>Aminpoor</surname><given-names initials="H">Hasibullah</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref><email>hasibaminpoor786@gmail.com</email></contrib><aff id="aff1"><label>a</label>Faculty of Medicine, Georgian American University, Manifest Medical Research Co., Tbilisi, Georgia</aff><aff id="aff2"><label>b</label>Faculty of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan</aff><aff id="aff3"><label>c</label>Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey</aff><aff id="aff4"><label>d</label>Faculty of Medicine, Kabul University of Medical Sciences &#8220;Abu Ali Ibn Sina&#8221;, Kabul, Afghanistan</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding author. Address: Faculty of Medicine, Kabul University of Medical Sciences &#8220;Abu Ali Ibn Sina&#8221;, Ata Turk Avenue, Jamal Mena, 3rd District, Kabul 1001, Afghanistan. Tel.: +93 730097097. E-mail: <email>hasibaminpoor786@gmail.com</email> (H. Aminpoor).</corresp></author-notes><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>18</day><month>11</month><year>2025</year></pub-date><volume>88</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">504038</issue-id><fpage>999</fpage><lpage>1000</lpage><history><date date-type="received"><day>10</day><month>10</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>11</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>06</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-07 09:25:13.140"><day>07</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0</ext-link> (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ms9-88-0999.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ms9-88-0999.pdf"/><abstract><p>The integration of artificial intelligence (AI) into soft tissue sarcoma (STS) diagnostics represents a significant leap toward precision oncology. AI-driven genomic tools, especially in the detection of fusion genes, enhance diagnostic sensitivity, speed, and accuracy, facilitating improved patient stratification and personalized therapy. The convergence of AI with multi-omic data &#8211; including transcriptomic, epigenomic, and imaging datasets &#8211; offers a comprehensive view of sarcoma biology and supports earlier detection and optimized treatment selection. However, effective implementation requires international collaboration, standardized reporting frameworks, and continuous clinician education. AI holds transformative potential to advance the precision, efficiency, and clinical impact of STS management.</p></abstract><kwd-group><kwd>artificial intelligence</kwd><kwd>genomics</kwd><kwd>precision oncology</kwd><kwd>soft tissue sarcoma</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><italic toggle="yes">Dear Editor</italic>,</p><p>Hereditary breast and ovarian cancer (HBOC) syndromes, primarily due to germline BRCA1/2 mutations, significantly elevate lifetime cancer risk. BRCA1/2 mutations account for 10&#8211;20% of all ovarian cancers, with mutation carriers facing up to a 44% lifetime risk<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup>. Early detection is critical, enabling preventive strategies and surveillance. In high-income countries like the UK, universal BReast CAncer (BRCA) testing for ovarian cancer is now considered cost-effective<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup>. However, access remains limited in low- and middle-income countries. In India, population-wide BRCA screening could prevent nearly 97 000 ovarian cancer cases and 78 000 deaths<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup>, underscoring the global need for scalable, cost-effective HBOC diagnostics.</p><p>Artificial intelligence (AI) offers promising solutions across the HBOC care continuum. AI-powered chatbots, for instance, are being used to pre-screen patients based on family history. A US study using the chatbot &#8220;Gia&#8221; found that trust, cost, and physician communication influenced patient engagement<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup>. Nonetheless, such tools can help extend genetic screening to underserved and rural populations. Similar automated prescreening tools are being deployed in the UK and Australia and hold promise for low-resource settings.</p><p>AI also enhances variant interpretation. Next-generation sequencing often detects rare variants of uncertain significance, complicating clinical decision making. Machine learning (ML) tools such as MARGINAL apply ACMG-AMP criteria to classify BRCA1/2 variants with up to 98% accuracy<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup>. BRCA-specific ML classifiers also outperform generic models in pathogenicity prediction<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup>, improving consistency in genetic test interpretation. As gene panels expand to include PALB2, RAD51, and TP53, ML algorithms incorporating population data and conservation scores will be essential, especially if trained on diverse, multiethnic cohorts.</p><p>AI applications are also advancing tumor genomics. A notable example is DeepHRD, a convolutional neural network that predicts homologous recombination deficiency (HRD) from H&amp;E pathology slides<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>. Trained on over 1400 breast and ovarian tumors, DeepHRD achieved an AUC of 0.81 and identified 1.8&#8211;3.1 times more HRD-positive cases than standard assays<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>. This approach can reveal candidates for targeted therapies like PARP inhibitors, directly from routine pathology.</p><p>In summary, AI is transforming HBOC diagnosis from improving risk screening to enhancing variant classification and detecting genomic signatures via histopathology. These technologies offer scalable, equitable solutions, particularly for underserved populations. However, their integration requires careful clinical validation, diverse data representation, ethical oversight, and clinician education. With global collaboration, AI can help close the gap in hereditary cancer detection and care. We confirm that no AI tools were utilized in the conduct or writing of this manuscript, in accordance with the TITAN checklist<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup>.</p></body><back><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><fn-group><fn fn-type="COI-statement"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="equal"><p>Published online 18 November 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>Not applicable.</p></sec><sec><title>Consent</title><p>Not applicable as the study includes publicly available data.</p></sec><sec><title>Sources of funding</title><p>The authors received no funding.</p></sec><sec><title>Author contributions</title><p>M.Z.: Conceptualization, writing &#8211; original draft. M.K.: Writing &#8211; review and editing, validation, supervision. M.B.: Writing &#8211; review and editing, visualization. H.K.: Project administration, writing &#8211; review and editing. H.A.: Validation, supervision.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec><sec><title>Guarantor</title><p>Hasibullah Aminpoor.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>Not applicable.</p></sec><sec><title>Provenance and peer review</title><p>Noncommissioned, externally peer-reviewed.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>Not applicable.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Manchanda</surname><given-names>R</given-names></name><name name-style="western"><surname>Hollington</surname><given-names>J</given-names></name></person-group>. <source>Whitepaper on Hereditary Ovarian Cancer</source>. World Ovarian Cancer Coalition; <year>2024</year>.</mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wollney</surname><given-names>EN</given-names></name><name name-style="western"><surname>Sims</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ricks-Santi</surname><given-names>LJ</given-names></name><etal/></person-group>. <article-title>Implementing a chatbot to promote hereditary breast and ovarian cancer genetic screening in women&#8217;s health: identifying barriers and facilitators to screening adoption</article-title>. <source>BMC Public Health</source><year>2025</year>;<volume>25</volume>:<fpage>2516</fpage>.<pub-id pub-id-type="pmid">40684177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-025-23488-4</pub-id><pub-id pub-id-type="pmcid">PMC12276685</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karalidou</surname><given-names>V</given-names></name><name name-style="western"><surname>Kalfakakou</surname><given-names>D</given-names></name><name name-style="western"><surname>Papathanasiou</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>MARGINAL: an automatic classification of variants in BRCA1 and BRCA2 genes using a machine learning model</article-title>. <source>Biomolecules</source><year>2022</year>;<volume>12</volume>:<fpage>1552</fpage>.<pub-id pub-id-type="pmid">36358902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom12111552</pub-id><pub-id pub-id-type="pmcid">PMC9687470</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DB</given-names></name><etal/></person-group>. <article-title>Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants</article-title>. <source>Sci Rep</source><year>2023</year>;<volume>13</volume>:<fpage>10478</fpage>.<pub-id pub-id-type="pmid">37380723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-37698-6</pub-id><pub-id pub-id-type="pmcid">PMC10307865</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergstrom</surname><given-names>EN</given-names></name><name name-style="western"><surname>Abbasi</surname><given-names>A</given-names></name><name name-style="western"><surname>D&#237;az-Gay</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Deep learning artificial intelligence predicts homologous recombination deficiency and platinum response from histologic slides</article-title>. <source>J Clin Oncol</source><year>2024</year>;<volume>42</volume>:<fpage>3550&#8211;60</fpage>.<pub-id pub-id-type="pmid">39083703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.02641</pub-id><pub-id pub-id-type="pmcid">PMC11469627</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Transparency in the reporting of Artificial INtelligence &#8211; The TITAN guideline</article-title>. <source>Prem Sci</source><year>2025</year>;<volume>10</volume>:<fpage>100082</fpage>. doi:<pub-id pub-id-type="doi">10.70389/PJS.100082</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>